Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Toronto-Dominion Bank — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Toronto-Dominion Bank trades at $120.25 (market cap $198.82B). The key difference: Toronto-Dominion Bank is far larger — about 5× Alnylam Pharmaceuticals, Inc.'s market cap, and Toronto-Dominion Bank pays a 2.69% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TD | |
|---|---|---|
Market Cap | $39.89B | $198.82B |
Sector | Health | Financials |
52-Week High | $491.22 | $122.25 |
52-Week Low | $278.09 | $72.55 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TD stock trades at $120.53, up 0.65% with a bullish technical signal and strong analyst consensus. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.71. Revenue grew to $61.28B in 2025 with a robust 23.38% net income margin, though cash flow from operations was negative. The stock trades at a P/E of 20.08 and P/B of 2.51, with a consensus price target of $153.00 representing 27% upside potential.
TD presents a compelling investment case with strong profitability metrics, consistent earnings beats, and positive analyst sentiment. Key risks include volatile operating cash flows, rising debt-to-asset ratios, and economic sensitivity. The current valuation appears reasonable relative to growth prospects, supported by institutional confidence and dividend stability. Upside potential exists if the company maintains its earnings momentum and executes on operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
